GWM
ALDX icon

Geneos Wealth Management’s Aldeyra Therapeutics ALDX Stock Holding History

Geneos Wealth Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-250
Closed -$2K – 2400
2018
Q4 		$2K Hold
250
– – ﹤0.01% 2167
2018
Q3 		$3K Hold
250
– – ﹤0.01% 2154
2018
Q2 		$1K Hold
250
– – ﹤0.01% 2165
2018
Q1 		$1K Hold
250
– – ﹤0.01% 2085
2017
Q4 		$1K Sell
250
-200
-44% -$1.32K ﹤0.01% 2079
2017
Q3 		$3K Buy
+450
New +$2.35K ﹤0.01% 1869

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geneos Wealth Management's ALDX Position: Q1 2019 in Review

Geneos Wealth Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2019, closing a stake of 250 shares — an estimated $2K sold.

Geneos Wealth Management first reported a position in ALDX in Q3 2017 and held it in 6 quarters. The position peaked at $3K in Q3 2018. 79 funds tracked by Wall St. Rank hold ALDX as of Q1 2019.

  • Geneos Wealth Management reported no remaining Aldeyra Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Geneos Wealth Management sold 250 Aldeyra Therapeutics shares in Q1 2019, an estimated $2K.
  • Geneos Wealth Management first reported a position in Aldeyra Therapeutics in Q3 2017 and held it in 6 quarters.
  • Geneos Wealth Management's Aldeyra Therapeutics position peaked at $3K in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2019.

Based on Geneos Wealth Management's 13F filing for Q1 2019, filed 7 Sep 2021.